Insider · CIK 1225471
George L Sing
Director at Regeneron Pharmaceuticals REGN
Full history from EDGAR: holdings now, every transaction and Form 144 planned sales
Open-market buys0
Open-market sales9
Bought$0
Sold$20.4M
Every trade, with what the company filed around it
Open-market buys and sales as each Form 4 states them, newest first.
How these figures work
Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. Holding after is what the filing reports they held after the trade, with the change in their holding.
| Date | Company | Trade | Value | Holding after | Notes |
|---|---|---|---|---|---|
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Option exercise 7,830 sh at $376.69 The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $2.9M | 38,837 | The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Option exercise 7,439 sh at $380.95 The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $2.8M | 46,276 | The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 1,224 sh at $960.57 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $1.2M | 45,052 −3% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 540 sh at $961.85 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $519K | 44,512 −1% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 2,522 sh at $962.61 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $2.4M | 41,990 −6% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 4,338 sh at $963.47 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $4.2M | 37,652 −10% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 2,670 sh at $964.57 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $2.6M | 34,982 −7% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 7,073 sh at $965.38 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $6.8M | 27,909 −20% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 1,522 sh at $966.27 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $1.5M | 26,387 −5% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 1,040 sh at $967.07 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $1M | 25,347 −4% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 | Regeneron Pharmaceuticals REGN | Sold 200 sh at $970.18 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. | $194K | 25,147 −1% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Jan 2, 2025 | Regeneron Pharmaceuticals REGN | Award 166 sh 63 days after the company's 10-Q filed Oct 31, 2024. | 27,828 | 63 days after the company's 10-Q filed Oct 31, 2024. | |
| Dec 31, 2024 | Regeneron Pharmaceuticals REGN | Option exercise 3,338 sh at $413.33 61 days after the company's 10-Q filed Oct 31, 2024. | $1.4M | 29,610 | 61 days after the company's 10-Q filed Oct 31, 2024. |
| Dec 31, 2024 | Regeneron Pharmaceuticals REGN | Tax withholding 1,948 sh at $708.19 61 days after the company's 10-Q filed Oct 31, 2024. | $1.4M | 27,662 | 61 days after the company's 10-Q filed Oct 31, 2024. |
| Jan 2, 2024 | Regeneron Pharmaceuticals REGN | Award 135 sh 61 days after the company's 8-K filed Nov 2, 2023. | 26,349 | 61 days after the company's 8-K filed Nov 2, 2023. |
Open-market trades are Form 4 transaction codes P (purchase) and S (sale). Planned sales are those the filing marks as made under a Rule 10b5-1 plan. A P-code buy at the offering price within a day of the company's FWP, 424B prospectus or offering 8-K is marked Bought in the offering and left out of open-market buy counts and cluster buys. Prices and values are as stated in each Form 4. Stock prices aren't shown on this page. Not investment advice.